UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                          WASHINGTON, D.C. 20549

                               FORM 10-QSB/A

      QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 OR 15(d) OF THE
                     SECURITIES EXCHANGE ACT OF 1934

             For the quarterly period ended March 31, 2002
                                            --------------

                     Commission file number  000-29171

                                MED GEN, INC.
       -----------------------------------------------------------------
       [Exact name of small business issuer as specified in its charter]

        Nevada                                          65-0703559
------------------------                    ---------------------------------
(State of incorporation)                    (IRS Employer Identification No.)


         7284 W. Palmetto Park Road, Suite 106, Boca Raton, FL 33433
         -----------------------------------------------------------
                    (Address of principal executive offices)

                                 (561) 750-1100
                         ---------------------------
                         (Issuer's telephone number)

Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that
the registrant was required to file such reports), and (2) has been subject
to such filing requirements for the past 90 days.

                       Yes [X]           No [ ]

Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date.

Common Stock, Par Value $.001 per share

10,392,216 Shares outstanding as of March 31, 2002.

Transitional Small Business Disclosure Format (check one): Yes [ ]   No  [X]




<PAGE>     1


                                    INDEX
                                    -----

PART I.   FINANCIAL INFORMATION


Item 1.   Financial Statements

          Balance Sheet - March 31, 2002 (Unaudited)

          Statements of Operations - Three months and Six months ended
          March 31, 2002 and 2001 (Unaudited).

          Statements of Cash Flows - Six months ended March 31, 2002
          and 2001 (Unaudited).

          Notes to Financial Statements (Unaudited).

Item 2.   Management's Discussion and Analysis of Financial
          Condition and Results of Operations.

PART II.  OTHER INFORMATION

Item 4.   Submission of Matters to a Vote of Securityholders

Item 5.   Other Information

Item 6.   Exhibits and Reports on Form 8-K


SIGNATURES



<PAGE>    2


                          MED GEN, INC.


This Form 10-QSB for the period ended March 31, 2002, has been
amended from the original filing of May 14, 2002.  During September
2002 the Company determined that it had incorrectly recorded
$350,000 of convertible debentures described in Note 6 as
convertible preferred stock. This amount has been reclassified to
convertible debentures in the accompanying financial statements. The
adjustment had no effect on the net loss or net loss per share for the
period ended March 31, 2002.


<PAGE>    3


                    PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

                                Med Gen, Inc.
                                Balance Sheet
                               March 31, 2002
                                 (Unaudited)

                                  Restated

ASSETS

Current Assets
  Cash and cash equivalents                                      $  402,815
  Accounts receivable                                               762,146
  Inventory                                                         162,058
  Officer advances                                                   93,494
  Other current assets                                               24,536
                                                                 ----------
      Total Current Assets                                        1,445,049
                                                                 ----------

Property and Equipment, net                                          95,467
                                                                 ----------

Other Assets
  Deposits                                                           87,109
  Due from affiliates                                                60,134
  Other                                                              12,125
                                                                 ----------
                                                                 $1,699,884
                                                                 ==========
LIABILITIES AND STOCKHOLDERS' EQUITY

Current Liabilities
  Accounts payable and accrued expenses                          $  454,903
  Notes payable - officers                                          100,000
  Notes payable                                                     500,000
  Convertible debentures                                            159,500
                                                                 ----------
      Total Current Liabilities                                   1,214,403
                                                                 ----------

Convertible debentures                                              350,000
                                                                 ----------
Stockholders' Equity
  Preferred stock, $.001 par value, 5,000,000 shares
    authorized:
  Series A 8% cumulative, convertible, 1,500,000 shares
     authorized                                                           -
  Undesignated, 3,500,000 shares authorized                               -
  Common stock, $.001 par value, 20,000,000
    shares authorized, 10,392,216 shares
    issued and outstanding                                           10,392
  Paid in capital                                                 3,583,283
  Accumulated (deficit)                                          (3,448,194)
                                                                 ----------
                                                                    145,481
  Treasury stock, at cost 20,000 shares                             (10,000)
                                                                 ----------
                                                                    135,481
                                                                 ----------
                                                                 $1,699,884
                                                                 ==========


           See accompanying notes to the financial statements.



<PAGE>    4


                                 Med Gen, Inc.
                          Statements of Operations
    For the Three Months and Six Months Ended March 31, 2002 and 2001
                                  (Unaudited)

                                   Restated


<TABLE>
<CAPTION>
                                            Three Months                        Six Months
                                    ---------------------------        ---------------------------
                                       2002             2001               2002            2001
                                   ----------       -----------        -----------      ----------
<S>                                <C>              <C>                <C>              <C>

Net Sales                          $  936,451       $   362,173        $ 1,889,330      $  767,331

Cost of Sales                         373,482            90,803            644,514         218,136
                                   ----------       -----------        -----------      ----------
                                      562,969           271,370          1,244,816         549,195
                                   ----------       -----------        -----------      ----------

Operating expenses:
  Non cash stock compensation         233,992                 -            233,992               -
  Selling, general and
    administrative expenses           446,030           366,296          1,130,060         612,129
                                   ----------       -----------        -----------      ----------
                                      680,022           366,296          1,364,052         612,129

(Loss) from operations               (117,053)          (94,926)          (119,236)        (62,934)

Other (income) expense:
  Other (income) expenses                   -           (13,373)           (22,884)        (10,738)
  Interest expense                     14,988                 -             32,431               -
  Non cash interest expense                 -                 -            210,000               -
                                   ----------       -----------        -----------      ----------
                                       14,988           (13,373)           219,547         (10,738)
                                   ----------       -----------        -----------      ----------

Net (loss)                           (132,041)          (81,553)          (338,783)        (52,196)
                                   ==========       ===========        ===========      ==========

Per share information - basic
  and fully diluted:

 Weighted average shares
   outstanding                     10,392,216         5,009,716         10,350,108       4,725,678
                                   ==========       ===========        ===========      ==========

 Net (loss) per share              $    (0.01)      $     (0.02)       $     (0.03)     $    (0.01)
                                   ==========       ===========        ===========      ==========
</TABLE>


           See accompanying notes to the financial statements.



<PAGE>    5

                                 Med Gen, Inc.
                          Statements of Cash Flows
               For the Six Months Ended March 31, 2002 and 2001
                                 (Unaudited)

                                   Restated

<TABLE>
<CAPTION>
                                                     2002            2001
                                                 -----------     -----------
<S>                                              <C>             <C>
Cash flows from operating activities:
 Net cash provided by (used in) operating
   activities                                    $  (415,391)    $    17,721
                                                 -----------     -----------

Cash flows from investing  activities:
 Net cash (used in) investing activities             (57,581)        (48,956)
                                                 -----------     -----------

Cash flows from financing activities:
 Net cash provided by financing activities           867,800          63,250
                                                 -----------     -----------

Net increase in cash                                 394,828          32,015

Beginning - cash and cash equivalents                  7,987              27
                                                 -----------     -----------

Ending - cash and cash equivalents               $   402,815     $    32,042
                                                 ===========     ===========
</TABLE>

           See accompanying notes to the financial statements.



<PAGE>     6


                          MED GEN, INC.
                  NOTES TO FINANCIAL STATEMENTS
                         MARCH 31, 2002
                           (UNAUDITED)


(1)	Basis Of Presentation

The accompanying unaudited financial statements have been prepared in
accordance with generally accepted accounting principles  (GAAP) for
interim financial information and Item 310(b) of Regulation S-B. They do
not include all of the information and footnotes required by GAAP for
complete financial statements. In the opinion of management, all
adjustments (consisting only of normal recurring adjustments) considered
necessary for a fair presentation have been included.

The results of operations for the periods presented are not necessarily
indicative of the results to be expected for the full year.  For further
information, refer to the financial statements of the Company as of
September 30, 2001 and for the two years then ended, including notes
thereto included in the Company's Form 10-KSB.

(2)	Earnings Per Share

The Company calculates net income (loss) per share as required by
Statement of Financial Accounting Standards (SFAS) 128, "Earnings per
Share." Basic earnings (loss) per share is calculated by dividing net
income (loss) by the weighted average number of common shares
outstanding for the period. Diluted earnings (loss) per share is
calculated by dividing net income (loss) by the weighted average number
of common shares and dilutive common stock equivalents outstanding.
During periods when anti-dilutive commons stock equivalents are not
considered in the computation.

(3)	Inventory

Inventory is stated at the lower of cost, determined on a first in,
first out basis, or market value. Inventory consists principally of
finished goods and packaging materials.

(4)	Notes Payable

During October 2001 the Company refinanced certain loans into a $350,000
note payable due during January 2002 with interest at 7.5% per annum. As
additional consideration for the loan, the Company issued 1,500,000
shares of its common stock (see Note 7). During March 2002 the Company
refinanced this obligation into a $500,000 note payable. This note bears
interest at 8% per annum, requires interest payments of $3,333 per month
and is due on March 23, 2003.

(5)	Income Taxes

The Company accounts for income taxes under SFAS 109, "Accounting for
Income Taxes", which requires use of the liability method. SFAS 109
provides that deferred tax assets and liabilities are recorded based on
the differences between the tax bases of assets and liabilities and
their carrying amounts for financial reporting purposes, referred to as
temporary differences. Deferred tax assets and liabilities at the end of
each period are determined using the currently enacted tax rates applied
to taxable income in the periods in which the deferred tax assets and
liabilities are expected to be settled, or realized.

The Company's deferred tax asset of approximately $1,100,000 resulting
from net operating loss carryforwards aggregating approximately
$3,400,000 is fully offset by a valuation allowance. The Company has


<PAGE>    7


recorded a valuation allowance to state its deferred tax assets at
estimated net realizable value due to the uncertainty related to
realization of these assets through future taxable income.

The provision for income taxes differs from the amount computed by
applying the statutory rate of 34% to income before income taxes due to
the effect of the net operating loss.

(6)	Convertible Debentures

During February and March 2002 the Company issued $350,000 of 8%
cumulative convertible debentures  due in May 2004 for cash aggregating
$350,000. The debentures are convertible into common shares of the
Company as follows:

At any time after the Company's common stock price exceeds $3 per
share for a period of ten consecutive trading days the holder may
convert 50% of the value of the debenture into common stock at the rate
of $.10 per common share (election to convert).

The remaining 50% of the debenture may be redeemed by the Company for
cash or may be converted into the number of common shares of the Company
determined by dividing the balance of the value of the debenture by the
common stock price at the time of the election to convert.

Notwithstanding the above, on the 25th monthly anniversary of the date
of the investments the debentures automatically convert into common
stock as follows:

50% of the value of the debentures converts into common stock at the
rate of $.10 per common share and the remaining 50% of the value of the
debentures converts into the number of common shares determined by
dividing the balance of the value of the debentures by the common stock
price at the 25th monthly anniversary.

The shares of common stock to be issued upon conversion are subject to
certain registration rights.

Any difference between the fair market value of the common shares and
the conversion price shall be recorded as additional interest on the
debentures at the time of the conversion.


(7)	Stockholders' Equity

Common stock

During October 2001 the Company issued 735,000 shares of common stock
for consideration aggregating $147,000, pursuant to the exercise of
stock options by a consultant.

During October 2001 the Company issued 1,500,000 shares of common stock
as partial consideration for a loan (see Note 4). The Company charged
the fair value of these shares of $210,000 to interest expense during
the period ended March 31, 2002.

During January 2002 the Company issued 83,300 shares of common stock in
exchange for services. The Company charged the fair value of theses
shares of $19,992 to operations during the period ended March 31, 2002.



<PAGE>    8


During the period ended March 31, 2002 the Company agreed to issue
100,000 shares of common stock for cash aggregating $10,000. The
difference between the price paid for the shares and their fair market
value of $16,000 has been charged to operations during the period.

During the period ended March 31, 2002 the Company agreed to issue
800,000 shares of common stock for services. The Company charged the
fair value of these shares of $198,000 to operations during the period.

During the period ended March 31, 2002 the Company collected $202,000 of
receivables for common stock.

Stock-Based Compensation

During the period ended March 31, 2002 the Company issued options to
purchase 2,000,000 shares of common stock to officers and 50,000 shares
of common stock to non employees at $.23 per share.

SFAS 123 "Accounting for Stock-Based Compensation," requires the
Company to provide pro forma information regarding net income and
earnings per share as if compensation cost for the Company's stock
option plans had been determined in accordance with the fair value
based method prescribed in SFAS 123. The fair value of the option
grants is estimated on the date of grant utilizing the Black-Scholes
option pricing model. These results may not be representative of those
to be expected in future years.

Under the provisions of SFAS 123, the Company's net income (loss) and
earnings (loss) per share would have been reduced (increased) to the
pro forma amounts indicated below:

    Net (loss)
            As reported                           $(338,783)
            Pro forma                             $(518,783)

    Basic and diluted (loss) per share
            As reported                           $(.03)
            Pro forma                             $(.05)


(8)	Concentrations

During the period ended March 31, 2002 the Company derived 14%, 15% and
39% of its total sales from three major customers.


(9)	Correction Of An Error

During September 2002 the Company determined that it had incorrectly
recorded $350,000 of convertible debentures described in Note 6 as
convertible preferred stock. This amount has been reclassified to
convertible debentures in the accompanying financial statements. The
adjustment had no effect on the net loss or net loss per share for the
period ended March 31, 2002.





<PAGE>    9


Item 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
         AND RESULTS OF OPERATIONS
         -----------------------------------------------------------

RESULTS of OPERATIONS
---------------------

Three months ended March 31, 2002
Compared with three months ended March 31, 2001
-----------------------------------------------

For the 2002 second fiscal quarter ended March 31, 2002 ("Q-2"), Sales
increased 159% to $936,451. Gross Profit for the second fiscal quarter
was $562,969 versus $271,370 for the year ago quarter, an increase of
108%. Gross Profit Margins decreased to 60% of Sales in the quarter
versus 75% for the year ago quarter, reflecting the initiation of
overseas Sales in the current quarter (versus zero overseas Sales in
the year ago quarter).

While overseas Sales carry a lower margin of Gross Profit, overseas
distributors  pay-in-advance for their purchase orders.eliminating
completely any accounts receivable concerns or foreign exchange risk.

Operating expenses increased 22% to $446,030 for the second fiscal
quarter. Reflecting the implementation of internal operating cost
controls initiated last fiscal year, operating expenses represented
only 48% of Q-2 Sales versus a 101% proportion of Q-2 Sales in the
year ago quarter.

Operating Income was $116,452 for the second fiscal quarter. This
compares favorably with an Operating Loss of $94,926 in the year ago
quarter. For the second fiscal quarter, the Company reported a loss of
$0.01 per share (versus a loss of $0.02 per share in the year earlier
quarter). This loss reflects $233,992 in a non-cash expense in
connection with stock issued in lieu of cash compensation.

Six months ended March 31, 2002
Compared with six months ended March 31, 2001
---------------------------------------------

For the first six months of fiscal year 2002 ended March 31, 2002
("First Half"), Sales increased 146% to $1,889,330. Gross Profit for
the fiscal First Half was $1,244,816 versus $549,195 for the year ago
first half, an increase of 127%. Gross Profit Margins decreased to 66%
of Sales in the First Half versus 72% for the year ago first half, due
to the initiation of overseas Sales (versus zero in overseas Sales in
the year ago period).

While overseas Sales carry a lower margin of Gross Profit, overseas
distributors pay-in-advance for their purchase orders.eliminating
completely any accounts receivable concerns or foreign exchange risk.

Operating expenses increased 85% to $1,130,060 for the First Half.
Reflecting the implementation of internal operating cost controls
initiated last fiscal year, operating expenses represented 60% of
First Half Sales versus 80% of first half Sales in the year ago
period.

Operating Income (Core Income) was $114,756 for the First Half. This
compares favorably with an Operating Loss of $62,934 in the year ago
period.  For the fiscal First Half, the Company reported a loss of
$0.03 per share (versus a loss of $0.01 per share in the year earlier
period). This per share loss reflects charging $233,992 in a non-cash
expense in connection with stock issued in lieu of cash compensation.



<PAGE>    10



LIQUIDITY and CAPITAL RESOURCES
-------------------------------

Cash on hand increased by $394,918 at the end of the fiscal First Half
ended March 31, 2002 versus September 30, 2001.

Current Assets increased to $1,445,049 as of March 31, 2002 and were
$230,646 greater than Current Liabilities (which stood at $1,214,403
on that same date). This compares with Current Assets of $820,560 at
September 30, 2001 and were $312,511 less than Current Liabilities
(which stood at $1,133,071 at that same date).

Stockholders' Equity improved to $485,481 at the end of the fiscal
First Half, or $0.05 in Tangible Book Value Share versus a
Stockholders' Deficit of $163,477 at September 30, 2001, an increase
of $648,958.

The Company believes that it has sufficient existing Cash Resources,
Accounts Receivables and Internal Cash Flow to provide for all general
corporate operations in the foreseeable future.



                             PART II

Item 1.   LEGAL PROCEEDINGS
          -----------------

          Not applicable.

Item 2.   CHANGE IN SECURITIES
          --------------------

          Not Applicable

Item 3.   DEFAULTS UPON SENIOR SECURITIES
          -------------------------------

          Not Applicable

Item 4.   SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
          ---------------------------------------------------

          Not Applicable

Item 5.   OTHER INFORMATION
          -----------------

          Not Applicable

Item 6.   EXHIBITS AND REPORTS ON FORM 8-K
          --------------------------------

     (a)  There are no exhibits required to be filed for the
          period covered by this Report.

     (b)  There were no reports filed on Form 8-K for the
          period covered by this Report.




<PAGE>    11


                              SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.

                                          Med Gen Inc.
                                          (Registrant)

Date: September 6, 2002                   By:____/s/Paul B. Kravitz________
                                             Paul B. Kravitz
                                             Chief Executive Officer


                            CERTIFICATIONS

I, Paul Kravitz, certify that:

     1.     I have reviewed this quarterly report on Form 10-Q of Med
Gen, Inc.;

     2.     Based on my knowledge, this quarterly report does not
contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading with
respect to the period covered by this quarterly report; and

     3.    Based on my knowledge, the financial statements, and other
financial information included in this quarterly report, fairly present
in all material respects the financial condition, results of operations
and cash flows of the registrant as of, and for, the periods presented
in this quarterly report.

Date: September 6, 2002

      By: /s/ Paul Kravitz
         ----------------------------
         Paul Kravitz
         Chief Executive Officer


I, Jack Chien, certify that:

     1.     I have reviewed this quarterly report on Form 10-Q of Med
Gen, Inc.;

     2.     Based on my knowledge, this quarterly report does not
contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading with
respect to the period covered by this quarterly report; and

     3.     Based on my knowledge, the financial statements, and other
financial information included in this quarterly report, fairly present
in all material respects the financial condition, results of operations
and cash flows of the registrant as of, and for, the periods presented
in this quarterly report.

Date: September 6, 2002

      By: /s/ Jack Chien
         ---------------------------
         Jack Chien
         Chief Financial Officer, and Principal Accounting Officer


<PAGE>    12